JB Chemicals & Pharmaceuticals is currently trading at Rs. 97.50, up by 2.90 points or 3.07% from its previous closing of Rs. 94.60 on the BSE.
The scrip opened at Rs. 94.75 and has touched a high and low of Rs. 98.50 and Rs. 94.75 respectively. So far 33,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 98.50 on 22-Oct-2013 and a 52 week low of Rs. 67.20 on 25-Oct-2012.
Last one week high and low of the scrip stood at Rs. 95.45 and Rs. 90.15 respectively. The current market cap of the company is Rs. 825.00 crore.
The promoters holding in the company stood at 55.87% while Institutions and Non-Institutions held 4.93% and 39.20% respectively.
JB Chemicals & Pharmaceuticals (JBCPL) has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Tinidazole (for treatment of bacterial infection) 250 mg. and 500 mg. tablets.
The company plans to launch this prescription product in Q4 this year. The company would manufacture these formulations at its state-of-the-art manufacturing facility at Panoli in Gujarat.
The company’s US business has shown good growth in the last two years. The approval for Tinidazole has potential to further strengthen this business. In addition, the company expects approval of few more ANDAs already filed with USFDA. The company also plans to file more ANDAs to support its US business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: